Clinical Trial Update: Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial update for dapagliflozin in patients with inadequately controlled Type 1 diabetes; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 1 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2018-11-06